Status | Study |
Not yet recruiting |
Study Name: A Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects With Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) Condition: Advanced Solid Tumors Likely to Express Prolactin Receptor (PRLR) Date: 2017-05-05 Interventions: Drug: ABBV-176 Intravenous infusion |
Recruiting |
Study Name: Everolimus Therapy in People With Birt-Hogg-Dube Syndrome (BHD)-Associated Kidney Cancer or Sporadic Chromophobe Renal Cancer Condition: Renal Cancer Chromophobe Renal Cell Carcinoma Date: 2015-07-21 Interventions: Drug: Everolimus Everolimus is a commercial agent and is supplied by Novartis. |
Recruiting |
Study Name: Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Condition: Carcinoma of the Collecting Ducts of Bellini Chromophobe Renal Cell Ca Date: 2013-01-10 Interventions: Drug: Pazopanib Hydrochloride Given PO Other Names: |
Completed |
Study Name: Sorafenib Tosylate and Bevacizumab in Treating Patients With Advanced Kidney Cancer Condition: Chromophobe Renal Cell Carcinoma Clear Cell Renal Cell Carcinom Date: 2005-08-02 Interventions: Biological: Bevacizumab Given |